Table 1 Baseline characteristics.
N = 59 | |
|---|---|
Age, median (range) | 68 (48–83) |
Sex (%) | |
Male | 34 (58) |
Female | 25 (42) |
Race (%) | |
White | 53 (90) |
Black | 5 (8) |
Declined to answer | 1 (2) |
AL subtype (%) | |
Kappa | 13 (22) |
Lambda | 46 (78) |
2004 stage (%) | |
I | 14 (24) |
II | 17 (29) |
IIIa | 18 (30) |
IIIb | 8 (14) |
Missinga | 2 (3) |
2012 stage (%) | |
1 | 9 (14) |
2 | 18 (28) |
3 | 20 (36) |
4 | 10 (16) |
Missinga | 2 (6) |
Mean dFLC (SD), mg/L | 215.7 (224.6) |
Mean NT-proBNP (SD), pg/mL | 5310.3 (8445.1) |
Mean troponin T (SD), ng/mL(N = 34) | 0.07 (0.09) |
Mean hs troponin T (SD), ng/L (N = 23) | 12.6 (44) |
Cardiac (%) | 39 (66) |
Renal (%) | 34 (58) |
Number of organs (%) | |
1 | 21 (36) |
2 | 23 (39) |
≥3 | 15 (25) |
First line treatment | |
Cylcophosphamide/bortezomib/dexamethasone | 44 (75%) |
Cyclophsphamide/ixazomib/dexamethasone | 2 (3%) |
Cylcophosphamide/lenalidomide/dexamethasone | 1 (2%) |
Bortezomib/dexamethasone | 2 (3%) |
Daratumumab | 1 (2%) |
Stem cell transplant | 5 (9%) |
Unknown | 4 (6%) |
